Related Experiment Videos
Local cutaneous necrotizing lesions associated with interferon injections
U Krainick1, H Kantarjian, S Broussard
1Heidelberg University Medical School, Germany.
Summary
Long-term interferon (IFN) injections for chronic myelogenous leukemia (CML) can lead to severe skin reactions, including necrotizing vasculitis at injection sites. These painful lesions often require surgical intervention and are independent of IFN type or administration method.
Area of Science:
- Oncology
- Dermatology
- Pharmacology
Background:
- Interferon (IFN) therapy is used for chronic myelogenous leukemia (CML).
- Long-term intramuscular (i.m.) or subcutaneous (s.c.) injections of IFN-alpha, beta, and gamma are common treatment modalities.
- Cutaneous complications associated with IFN therapy require further investigation.
Observation:
- Seven patients with Philadelphia chromosome-positive (Ph+) CML treated with IFN developed cutaneous lesions at injection sites.
- Lesions were consistent with necrotizing vasculitis, confirmed by pathology in three cases.
- Skin reactions occurred irrespective of IFN type, administration route, therapy duration, disease stage, or cytogenetic response.
Findings:
- IFN injections can cause severe, long-lasting, painful skin lesions.
- Four patients experienced low-grade fever; cultures from lesions were negative for infection.
- Lesions often necessitated surgical debridement (5/7 patients) or slow resolution with conservative management.
Implications:
- Interferon therapy can induce significant cutaneous adverse events.
- The mechanism behind these reactions (IFN concentration, diluent, or immunologic) remains unclear.
- Awareness of these potential complications is crucial for managing CML patients on IFN therapy.